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Summary 
The role ofprostaglandin E 2 (PGE2) in the development of inflammatory symptoms and cyto- 
kine production  was  evaluated in  vivo using a  neutralizing  anti-PGE2  monoclonal antibody 
2B5.  In carrageenan-induced  paw inflammation,  pretreatment of rats with  2B5  substantially 
prevented the  development of tissue edema and hyperalgesia in affected paws.  The antibody 
was  shown  to  bind  the  majority  of PGE  2 produced  at  the  inflammatory site.  In  adjuvant- 
induced  arthritis,  the  therapeutic  administration  of 2B5  to arthritic  rats substantially reversed 
edema in affected paws. Anti-PGE2 treatment also reduced paw levels oflL-6 lq.NA and serum 
IL-6 protein without modifying tumor necrosis factor P,  NA levels in the same tissue.  In each 
model, the antiinflammatory efficacy of 2B5 was indistinguishable front that of the nonsteroidal 
antiinflammatory drug indomethacin,  which blocked the production of all PGs.  These results 
indicate that PGE  2 plays a major role in tissue edema, hyperalgesia, and IL-6 production at sites 
of inflammation, and they suggest that selective pharmacologic modulation of PGE  2 synthesis 
or activity may provide a useful means of mitigating the symptoms of inflammatory disease. 
T 
he host response to an inflammatory stimulus is char- 
acterized  by  the  development  of erythema,  edema, 
and pain at the site of tissue injury.  These symptoms result 
front the vasoactive and algesic effects of several substances 
such as histamine, bradykinin, and nitric oxide that are pro- 
duced in  response to  the  inflammatory stimulus  (1,  2).  In 
addition  to  these  mediators,  substantial  amounts  of PGs 
have been detected in inflammatory exudates.  Their con- 
tribution to the development of edema and pain in multi- 
ple  immunoinflammatory diseases  is  demonstrated  by the 
marked  therapeutic  effect that  nonsteroidal  antiinflamma- 
tory drugs  (NSAIDs) 1 exert through  the inhibition  of PG 
synthesis  (3-6).  PGs  appear  not  to  induce  inflammatory 
symptoms per se,  since  their  injection  into  normal  tissue 
elicits minimal swelling or pain.  Through the activation of 
specific  receptors  on  blood  vessels  and  sensory  nerves, 
however,  PGs  can  markedly  amplify  tissue  swelling  and 
pain at sites of inflammatory mediator production (7-12). 
Because of the potentiating effect of PGs on the inflam- 
matory response, the inhibition of PG synthesis by NSAIDs 
is one of the most widely used modalities for the treatment 
I  Abbreviations used in this paper: COX, cyclooxygenase;  EP, prostaglandin 
E; NSAID, nonsteroidal antiinflammatory  drug; PG, prostaglandin. 
of rheumatoid arthritis and other inflammatory diseases  (6, 
13).  Recent  evidence  indicates  that  the  antiinflammatory 
activity of NSAIDs results from the inhibition ofcyclooxy- 
genase-2  (COX-2),  a key enzyme in  the  metabolic path- 
way in  which  multiple biologically active PGs,  including 
PGD  2,  PGE  2,  PGF  2,  PGH  2,  PGI  2,  and  thromboxane  are 
synthesized from arachidonic acid (14-18). Thus far, little is 
known  about  the  relative  contribution  of  each  PG  to 
edema  formation  and  hyperalgesia.  PGE2  has  been  sus- 
pected to play a prominent role in tissue pathology, since it 
is present in high concentration in inflamed tissues  and ex- 
udate  fluids  (3,  16,  19),  and  when  administered  exoge- 
nously,  can enhance  pain and  edema in  tissue  exposed to 
inflammatory mediators (7-11). 
In the present study,  we  used  a neutralizing anti-PGE2 
mAb (2B5)  (20) to specifically examine the role of this PG 
in acute and chronic inflammation. We report that prophy- 
lactic  treatment  of rats  with  2B5  markedly reduced  paw 
edema  and  hyperalgesia  in  response  to  the  inflammatory 
stimulus  carrageenan.  PGE  2 was  quantitatively  bound  to 
2B5  in exudates of paws in which edema and hyperalgesia 
were diminished by antibody treatment.  Furthermore,  the 
therapeutic administration of 2B5 reversed paw edema and 
IL-6 production  in  rat  adjuvant  arthritis.  In  each  model, 
the  antiinflammatory  effects  afforded  by  selective  PGE  2 
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treated  with  the  NSAID  indomethacin.  These  findings 
demonstrate that PGE2 is an important mediator of vascular 
permeabililty,  hyperalgesia,  and  IL-6  production  in  vivo 
and  they  suggest  that  NSAIDs  suppress  certain  inflamma- 
tory responses by inhibition of PGE2 synthesis. 
Materials and Methods 
Carrageenan-induced Edema and Hyperalgesia.  The  induction  of 
paw inflammation with carrageenan was performed as previously 
described (18,  21). Paw edema and hyperalgesia were induced by 
the injection of 0.1  ml of a  0.1%  carrageenan  solution  in sterile 
saline  (FMC  Corp.,  Rockland,  ME)  into the hind  footpad  of a 
200-g male Sprague Dawley rat (Charles River Laboratories, Por- 
tage,  ME).  The  cOntralateral  paw  of each  animal  was  injected 
with saline and  served as the  normal  control.  Paw swelling was 
measured with a water displacement plethysmometer at selected 
times  after  carrageenan  injection.  The  edema  response  is  ex- 
pressed  as  the  difference  in  paw  volume  between  the  carra- 
geenan- and saline-injected paws of each animal. 
A hyperalgesic response to thermal stimulation was determined 
in the same animals by the method of Hargreaves et al. (22).  Hind 
paws were exposed to radiant  heat emitted from a high intensity 
projection bulb  at selected times after injection. The  amount  of 
time in which each hind paw remained in contact with the heat 
source  was  measured  to  the  nearest  0.1  s.  The  hyperalgesic re- 
sponse is expressed as the difference in the latency withdrawal pe- 
riod between carrageenan- and saline-injected paws of each animal. 
In  certain  experiments,  rats  were  adnfinistered  indomethacin 
by  oral  gavage  in  0.5%  Methocel/0.025%  Tween  80  (Sigma 
Chemical Co., St. Louis, MO)  1 h before carrageenan, Other rats 
were injected intraperitoneally with mouse ascites fluid contain- 
ing the mouse anti-PGE2 mAb, 2B5 or isotype-matched MOPC21 
lgG1  myeloma protein  (Sigma Chemical Co.)  18 h  before carra- 
geenan injection. The concentration of mouse IgGi in ascites fluid 
was determined by a sandwich EL1SA using species-specific anti- 
mouse  IgG  antibodies  (Jackson  ImmunoResearch  Laboratories, 
West Grove, PA) as the capture and detecting reagents,  as previ- 
ously described  (20).  The ELISA was also  used to quantitate  the 
circulating level of 2B5 in the plasma of passively immunized rats. 
The  carrageenan  model of paw  edema  was  modified by  the 
method ofHiggs et al. (23) to evaluate the inflammatory activity of 
exogenously administered PGs. Briefly, rats received a 30-mg/kg 
oral dose of indomethacin to prevent production  of endogenous 
PGs.  1 h  later, rats  were injected in the hind footpad with carra- 
geenan or with carrageenan  plus  100  ng of PGE2 or PGI 2 (Bio- 
tool,  Plymouth  Meeting,  PA).  Paw  edema  was  then  measured 
over a 3-h period to evaluate the ability of individual PGs to re- 
constitute the swelling response. 
Adjuvant Arthritis.  Arthritis  was  induced  in  male  Lewis  rats 
(Harlan,  Indianapolis,  IN)  by footpad injection  of Mycobacterium 
butyricum in mineral oil (Difco Laboratories,  Detroit,  MI)  as de- 
scribed  previously  (24,  25).  Dexamethasone  and  indomethacin 
(Sigma Chemical Co.) were suspended  in Methocel/Tween and 
adnfinistered twice daily by gavage at dosages of 0.1 and 2 mg/kg, 
respectively. 2B5 and MOPC21 ascites were administered daily at 
a dose of 10 mg/kg by intraperitoneal injection. Treatments were 
initiated on day 15 postadjuvant injection and continued until fi- 
nal assessment of paw volume of uninjected contralateral paws on 
day  21.  Previous results showed substantial  paw  swelling by day 
15,  as well as maximal levels of COX-2 protein and PGE2 in ar- 
thritic paws (25). 
Eicosanoid Analysis.  PG and thromboxane  levels in paw exu- 
dates were measured by ELISA (Cayman Chemical Co., Ann Ar- 
bor,  MI). To facilitate the recovery of eicosanoids from paw tis- 
sue, paws were removed from rats  after euthanasia with CO  2 and 
injected immediately with 0.1  ml of saline containing 30 IxM in- 
domethacin. Paws were centrifuged at  1,200 g, and the expressed 
fluid was analyzed for eicosanoids by ELISA. 
Cytokine Analysis.  Paws of selected animals were removed on 
day  21  to  evaluate  the  effects  of pharmacologic  inhibitors  and 
2B5  on IL-6 and  TNF  P,  NA production.  Total RNA  was  ex- 
tracted from frozen and  pulverized paws  and  hybridized to 32p_ 
antisense probes complementary to rat IL-6 and TNF mRNA se- 
quences  as previously described  (18,  25).  Cytokine  1KNA  levels 
were quantified by nuclease protection assay using an NPA I1 kit 
(Ambion  Inc.,  Austin,  TX),  as  described  by  the  manufacturer. 
l<Nase  digests  were  fractionated  on  an  8%  polyacrylamide  gel 
containing 7.5  M  urea and  the relative intensities  of RNA frag- 
ments were determined  using a phosphoimager  (Molecular Dy- 
namics, Sunnyvale, CA). Constitutive levels of GAPDH P,  NA were 
measured  in parallel to  correct for differences in sample  loading 
among  treatment  groups.  IL-6 protein  levels in rat  serum  were 
estimated by a 7TD1  cell bioassay, as previously described (25). 
Results 
Pharmacokinetics of 2B5 in Rats.  To  determine  the  time 
that is required to achieve maximal plasma levels of 2B5  in 
the rat,  the concentration  of 2B5  was measured  in periph- 
eral blood at selected times after a single intraperitoneal  in- 
jection of antibody. 2B5 was detectable in the plasma of re- 
cipient  animals  as  early  as  i  h  after  injection,  and  peak 
levels of 60  ~g/ml  were  attained  within  6  h  (Fig.  1).  2B5 
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Figure 1.  Time course of 2B5 absorption in rat plasma. The circulating 
level of the mouse  anti-PGE~  mAb 2B5  (lgGl,K) was measured  in rat 
plasma at  indicated  times  after  injection.  2B5  was  administered  in  the 
form of ascites fluid to Sprabme Dawley rats (it =  6) as a single 5 mg/kg 
dose by intraperitoneal  injection.  The concentration  of mouse lgG in rat 
plasma was determined  by a sandwich  EIA using anti-mouse lgG anti- 
bodies that demonstrated  negligible cross-reactivity with rat lg. 
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Figure  2.  Carrageenan induced eicosanoid production in rat paws. COX products in paws of Sprague Dawley rats injected  locally  with 1% carra- 
geenan or saline were measured by ELISA at indicated times after injection. Each data point represents mean nanograms of eicosanoid/paw -+ SE for six 
animals/group. 
continued  to circulate at high levels when paw inflamma- 
tion was induced  12 h later. 
Effect of 2B5 on Acute Paw Inflammation.  To  examine  the 
role of PGE2 in acute inflammation, we evaluated the effect 
of 2B5 in a rat model of carrageenan induced paw edema. 
Local injection  of carrageenan resulted in the  synthesis of 
multiple  COX  products  in  injected  paws  (Fig.  2).  En- 
hanced amounts of PGE2, 6-keto PGFI~ (the inactive me- 
tabolite of PGI2), and thromboxane B2 were detectable in 
paw exudates within 1 h after injection; within 3-5 h, each 
eicosanoid increased maximally three to fivefold over base- 
line.  In agreement with previous studies  (16,  18),  PG and 
thromboxane synthesis were prevented by indomethacin or 
a COX-2 selective inhibitor,  SC-58125,  administered  1 h 
before carrrageenan stimulation (not shown). 
The  kinetics  of local  eicosanoid  production  coincided 
with  the  development  of  edema  in  the  carrageenan- 
injected paw.  The small increase in paw volume that  oc- 
curred during the first h before PG production was not re- 
duced  by indomethacin  (Fig.  3).  This  result  agrees  with 
previous  findings  showing  that  bradykinin  and  histamine 
are  among the  first mediators detected  in  inflammmatory 
exudates after carrageenan stimulation (26).  In contrast, the 
substantial increase in paw swelling that developed after the 
first hour was blocked by NSAID  treatment,  indicating  a 
major role for PGs produced during the latter phase of the 
edema response. 
The  pharmacologic  attenuation  of paw  edema  by  in- 
domethacin was also observed in rats treated with the anti- 
PGE2 antibody (Fig.  3).  2B5 was administered  18 h before 
carrageenan to allow maximal distribution  of antibody be- 
fore induction  of paw inflammation.  Under  these  condi- 
tions, a 10 mg/kg dose of 2B5 was sufficient to completely 
prevent the NSAID-sensitive component of the edema re- 
sponse that occurred 1-3 h after carrageenan injection. The 
inhibitory  effect of 2B5  appeared  specific for PG-depen- 
dent inflammation, since the minor swelling that is insensi- 
tive  to  NSAID  treatment  was  not  affected.  A  MOPC21 
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control  protein,  matched  for  isotype  and  concentration, 
had no effect on paw edema at any time point. 
Reconstitution of Paw Edema with Exogenous PG.  A  ma- 
jor  role  for  PGE2  in  edema  formation  was  further  sup- 
ported  by  experiments  in  which  the  attenuation  of paw 
edema  by  indomethacin  was  completely reversed by the 
addition  of exogenous PGE  2 to the  carrageenan stimulus. 
As shown in Fig. 4, the magnitude of paw swelling induced 
in normal rats by carrageenan could be reproduced in in- 
domethacin-treated rats that were injected with carrageenan 
supplemented with purified PGE2. Not surprisingly, edema 
occurred more rapidly in  paws injected  with  carrageenan 
plus PGE  2 than in paws in which PGE2 was induced  after 
carrageenan injection. Exogenous PGI  2 also potentiated the 
edema response to carrageenan, but was less effective than 
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Figure  3.  2B5  and  indomethacin  reduce  carrageenan-induced  paw 
edema.  Sprague Dawley rats were treated with a  10 mg/kg dose of 2B5 
(I) or MOPC21 protein ([]) by intraperitoneal injection for 18 h or with 
a 30 mg/kg oral dose of indomethacin (O) or vehicle (S) for 1 h before 
injection of 0.1  ml of 1% carrageenan in saline  into the hind paw. The 
difference  in paw volume (mean +  SE) between carrageenan- and saline- 
injected  paws determined 1-3 h later is presented (n =  6). Vehicle, Carrageenan 
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Figure  4.  Reconstitution  of carrageenan-induced inflammation with 
PGs. Endogenous COX activity was blocked in Sprague Dawley rats by 
oral administration ofindomethacin  (30 mg/kg) 1 h before local injection 
ofcarrageenan (O) or carrageenan combined with PGE2 (11) or PGI2 ([~), 
100 ng/paw. A fourth group of rats injected with carrageenan under stan- 
dard conditions was included for comparison (O). Paw volume was deter- 
mined at the times indicated. Each point represents the difference in vol- 
ume (mean -+ SE) between stimulus-injected and saline-injected paws of 
each animal, n = 6 rats/group. 
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Figure  5.  2B5  neutralizes inflammatory effect of exogenous PGE2. 
The induction of paw edema in indomethacin-treated rats by coadminis- 
tration ofcarrageenan and PGs was performed as described in Fig. 4. Rats 
were pretreated with  10 mg/kg of 2B5 or MOPC21 by intraperitoneal 
route 18 h before local injection of the inflammatory stimulus. Paw vol- 
umes were measured 2 h later. Data are presented as the difference in vol- 
ume between stimulus-  and saline-injected  paws (mean -+ SE), n = 6/group. 
PGE 2.  Preadministration  of 2B5  to  indomethacin-treated 
animals reduced the swelling in paws injected with the car- 
rageenan-PGE 2  stimulus  to  that  elicited  by  carrageenan 
alone (Fig. 5). In contrast, 2B5 had no effect on paw swell- 
ing induced by carrageenan-PGI  2 under similar conditions. 
Taken together, these results underscore the importance of 
PGE2 as a mediator of vascular permeability and edema for- 
marion at sites of inflammation. 
Effect of 2B5 on Hyperalgesia.  In addition to edema, car- 
rageenan induced a hyperalgesic response in paws subjected 
to a thermal stimulus  (Fig. 6).  In agreement with previous 
studies (18, 22),  the injection ofcarrageenan into the foot- 
pad reduced the time period (withdrawal latency) in which 
the inflamed paw remained in contact with a heated surface 
compared to the saline-injected paw (2.5  +  0.4 s vs.  11.8  + 
0.6  s,  respectively). This  hyperalgesia was  typically inhib- 
ited 60-80%  in  rats pretreated with  a  maximally effective 
dose of indomethacin  (30 mg/kg) administered 1 h  before 
carrageenan  injection.  Strikingly,  the  intraperitoneal  ad- 
ministration of2B5  (10  mg/kg)  also reduced the hyperal- 
gesic response :'~  Neither 2B5  nor indomethacin ex- 
tended the withdrawal latency of control paws,  suggesting 
that  the  analgesic  effect  resulted  from  a  peripheral  rather 
than  central mode  of action.  These  results show  that  2B5 
and  indomethacin  were  equally  efficacious in  attenuating 
hyperalgesia associated with inflammation, and they further 
demonstrate  the  importance  of PGE 2 in potentiating pain 
at the inflammatory site. 
Dose Response Analysis of 2B5 and Indomethacin.  Dose  re- 
sponse studies indicated that 2B5 prevented edema and hy- 
peralgesia in a concentration-dependent manner. A  10 mg/kg 
dose of 2B5  caused maximal inhibition of both responses, 
and half maximal effects were obtained with :'-,1  mg/kg of 
antibody  (Fig.  7  A).  The  coincident  nature  of the  2B5 
dose-response curves suggests that the effective concentra- 
tion ofPGE 2 necessary to induce edema and hyperalgesia is 
similar.  Interestingly,  the  maximal  reduction  of both  re- 
sponses by 2B5 was comparable to that obtained with opti- 
mal doses ofindomethacin (Fig. 7 B). 
2BS-mediated Neutralization of PGE2.  To detemfine whether 
2B5 bound PGE 2 in vivo, we measured the amount of free 
PGE 2  in  paw  exudates  of  antibody-treated  animals  by 
ELISA. The data presented in Fig. 8 show the characteristic 
rise  in  PGE 2 levels in  paws  injected  3  h  previously with 
carrageenan,  as well as the inhibition of PGE  2 production 
by  indomethacin.  Paw  levels of free  PGE2  were  also  re- 
duced to baseline in rats treated 18 h  earlier with 10 mg/kg 
of 2B5,  a  dose that prevented the  PG-dependent increase 
in  paw  edema  and  hyperalgesia.  An  equivalent  dose  of 
MOPC21  did not alter PGE 2 levels in inflamed paws. The 
ability of 2B5 to reduce the levels of free PGE 2 induced by 
carrageenan to those in normal paw tissue strongly suggests 
that the antiinflammatory effect of 2B5  resulted from neu- 
tralization of PGE2 at the inflammatory site. 
Effect of 2B5  on  Paw Inflammation  in  Adjuvant  Arthritis. 
Since NSAIDs reverse paw edema and IL-6 production as- 
sociated with adjuvant arthritis (24, 25), we determined the 
extent to which  2B5  could produce similar antiinflamma- 
tory  effects  when  administered therapeutically to  arthritic 
rats. The data presented in Fig. 9 show that the injection of 
mycobacteria into the right hind footpad caused a  1-ml in- 
crease  in  the  volume  of arthritic  contralateral paws  com- 
pared to normal controls  14  d  after adjuvant injection. At 
this  time,  arthritic  rats  were  segregated  into  groups  and 
treated  daily with  indomethacin,  2B5,  or  dexamethasone 
for 7  d.  As observed in our previous study (25),  significant 
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Figure 6.  2B5 and indomethacin reduce car- 
rageenan-induced hyperalgesia. Sprague Daw- 
ley rats were treated with 2B5, MOPC21,  in- 
domethacin,  or  vehicle  under  conditions 
described in Fig. 3. The withdrawal latency pe- 
riod  of saline- and  carrageenan-injected paws 
(mean -+ SE) after exposure to a thermal stimu- 
lus was determined 3 h after injection (n =  6/ 
group). 
reversal of established edema  by indomethacin  and  dexa- 
methasone  was  observed by  day  18,  and  maximal  effects 
were attained by day 21. 
Paw swelling in arthritic rats was also reversed by thera- 
peutic  administration  of 2B5.  A  10  mg/kg  daily dose  of 
2B5  was  as  efficacious  as  the  maximal  oral  dose  of in- 
domethacin that could be safely administered during the 1 wk 
dosing  period.  The  antiinflammatory  effect  produced  by 
2B5 on days 18 and 21 was nearly identical to that obtained 
by blockade  of PG  synthesis with  indomethacin.  Neither 
agent was as effective as dexamethasone, which blocks the 
production of multiple inflammatory mediators in addition 
to  PGs.  Paw  swelling remained suppressed in indometha- 
cin-treated rats through  day 25,  yet it reappeared in  2B5- 
treated animals (not shown).  This loss of antiinflammatory 
activity was  associated with  a  rat antibody response to  the 
injected mouse antibody. 
Anticytokine Effects of 2B5.  We also examined the effect 
of 2B5  on  the  production  of the  inflammatory  cytokines 
IL-6 and TNF in adjuvant arthritis. As shown in Fig. 10 A, 
indomethacin and dexamethasone significantly blocked the 
substantial accumulation  of IL-6 mRNA  in  arthritic paws 
21  d  after adjuvant injection. The inhibitory effect of both 
drugs was also manifested systemically, since serum levels of 
IL-6 protein were reduced to normal levels (Fig.  10  B). In 
contrast to IL-6, TNF mRNA  levels were reduced only by 
dexamethasone,  indicating a  differential regulation  of cy- 
tokine production  by PGs  (Fig.  11).  An increase in  TNF 
RNA  was  observed in  one  of three  indomethacin-treated 
animals presented in  the figure;  however,  this finding was 
not representative of results obtained in three other experi- 
ments (not shown). 
We  used  2B5  to  address  the  role  of  PGE  2  in  IL-6 
mRNA  and protein production in this model. Data in Fig. 
10 B show that the therapeutic administration of 2B5 to ar- 
thritic rats beginning on day 14 caused a marked reduction 
in  IL-6 RNA  levels in  arthritic paws  and  serum  levels of 
IL-6 protein measured  21  d  after adjuvant injection.  The 
inhibitory effect, however, was less than what was achieved 
with indomethacin, suggesting that other PGs may also be 
involved in regulating IL-6. In contrast, TNF mRNA  lev- 
els in the same paws were not modulated by 2B5,  indicat- 
ing the antibody did not reduce total mRNA  levels in the 
inflamed tissue (Fig. 11). 
Discussion 
Global inhibition of PG synthesis by NSAIDs is a widely 
used  treatment of inflammatory symptoms associated with 
rheumatoid  arthritis  and  other  immunoinflammatory  dis- 
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Figure 7.  Concentration-response effects of 2B5 and indomethacin on 
carrageenan-induced inflammation. 2B5 and indomethacin were adminis- 
tered at indicated concentrations to Sprague Dawley rats as described in 
Fig. 3. Effects  on paw edema (O) and hyperalgesia  (O) were detemfined 3 h 
later.  The  percent  inhibition (mean  -+  SE)  of each  response is pre- 
sented, n =  6/group. 
Figure 8.  2B5 binds PGE  2 in carrageenan-injected paws. PGE2 levels 
in paw exudates were determined by ELISA 3 h after carrageenan or sa- 
line injection. Certain groups of  rats received 30 mg/kg indomethacin 1 h 
before carrageenan or 10 mg/kg 2B5  or MOPC21  18 h before carra- 
geenan as described in Fig. 3. Paw levels of free PGE  2 were determined 
by ELISA; data represent nanograms of PGE2/paw (mean -+ SE), n = 
6/group. 
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Figure  9.  Therapeutic attenuation of paw  edema by indomethacin, 
dexamethasone, and 2B5 in adjuvant arthritis. Arthritis was induced in 
male Lewis rats by injection of M.  butyricum in oil into the right hind 
footpad, as described in Materials and Methods. On day 14 after adjuvant 
injection, rats were segregated into groups and treated daily with dexa- 
methasone (0.1 mg/kg, bid, oral), indomethacin (2  mg/kg, bid, oral), 
2B5 or MOPC21 (10 mg/kg i.p., once per day) for 7 d. The volume of 
contralateral (uninjected)  arthritic paws was determined  by plethysmome- 
try on days 14, 18, and 21. Paw volume  of normal  littem~ates  was measured 
as controls. Data are presented as mean paw volume -+ SE, n = 6/group. 
The results are representative  of three independent  experiments. --m-, nor- 
mal; ~,  adjuvant; ~  , indomethacin; --[~-, 2B5; ~  MOPC21; 
+,  dexamethasone. 
eases  (13). In contrast, little is known about the therapeutic 
potential of blocking the synthesis or the activity of indi- 
vidual PGs. Our understanding is limited by the paucity of 
pharmacologic agents that  antagonize PGs  in a  type-spe- 
cific fashion (27, 28). For this reason, we have generated a 
neutralizing anti-PGE  2 mAb  (2B5)  to  address  the  role  of 
this  eicosanoid  in  acute  and  chronic  inflammation. We 
have previously shown that 2B5 binds PGE2 with an affin- 
ity of 100-300 pM,  is at least 200-fold more selective for 
PGE2 than for other COX products, and blocks the bind- 
ing  of  PGE  2  to  cell-surface  EP  receptors  (20).  In  the 
present study, we used 2B5 in a passive immunization study 
to investigate the inflammatory properties of PGE  2 in ani- 
mal  models  of  edema  and  pain  that  are  attenuated  by 
NSAIDs. 
Our  results  show  that  selective  inhibition  of  PGE2 
caused a profound antiinflammatory effect on NSAID-sen- 
sitive inflammation. We  observed  in acute  and  chronic 
responses that 2B5 attenuated both paw edema and hyper- 
algeria as effectively as indomethacin. The antibody, how- 
ever, had no inhibitory effect on the small increase in paw 
volume that was induced by carrageenan in rats depleted of 
endogenous PGs by indomethacin pretreatment, nor did it 
block the pain response of normal paws to a thermal stimu- 
lus. These results were consistent with the capacity of 2B5 
to modulate PG-dependent, but not PG-independent, in- 
flammation-associated responses.  Furthermore,  the  selec- 
tive  neutralization of PGE2  by  2B5  was  directly demon- 
Figure 10.  Inhibition of adjuvant-induced  IL-6 P,.NA and protein by 
dexamethasone, indomethacin, and 2B5. (A) Nuclease protection assay. 
Contralateral paws of adjuvant-injected  rats were recovered on day 21 after 
adjuvant  injection for P,  NA extraction  and analysis.  Autoradiogram  of IL- 
6 RNA (three paws/group) is shown above the mean relative intensities 
determined by phosphoimager analysis  of respective bands. The level of 
GAPI)H P,  NA detected by nuclease  protection was similar  in all samples 
(not shown). (/3) IL-6 bioassay. Serum was collected from Lewis rats 21 d 
after adjuvant  injection for I[.-6 quantitation.  IL-6 bioactivity  (U/n~) was 
determined by support of proliferation  Jmurine 7TD1 cells  and extrapola- 
tion t:rom a standard curve generated with mouse rlL-6. Data are presented 
as mean  U/ml +- SE, n = 6/group. 
strated  by  its  ability  to  block  the  potentiating effect  of 
exogenously  administered  PGE2  but  not  PGI  2  on  paw 
edema induced by carrageenan. ELISA analysis confirmed 
that 2B5  reduced the  level of free  PGE2 but not PGI2 in 
carrageenan-injected paws  to  normal  tissue  levels.  These 
findings provide direct evidence that 2B5 bound and neu- 
tralized PGE2 in vivo, and they indicate a likely nlechanism 
for its antiinflammatory  properties. 
Taken together,  these results indicate that PGE2 plays a 
critical role  in the  generation and maintenance of edema 
and  hyperalgesia  that  develops  at  sites  of  inflammation. 
Thus, the development of carrageenan-induced edema and 
hyperlagesia could be  substantially attenuated by prophy- 
lactic administration of 2B5.  Furthermore, therapeutic ad- 
ministration of 2B5  was  effective in reversing paw edema 
in rats  with  established arthritis.  A  significant decrease  m 
paw volume was observed within a few days after 2B5 ad- 
ministration to arthritic rats. Whereas PGI2 and thrombox- 
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tion analvs~s  ofTNF  RNA  m  ra~ 
adjuvant  arthritis.  TN'F  RN~t 
levels  in  arthnnc  pa~'s  of  r'a~ 
treated  with de,'c.ameth~or~r  ~.- 
domethacin,  or  2B5  reeve &'~:- 
mined  as  described  in  Fig.  IG. 
An  autoradiogram  of  p~t*~c~ed 
fragments (n  =  3  l~W',,'gmul  ~) i~ 
depicted  above  tl~  t'~e~'~'c 
mean  densitometr~'  um~  + 
for each group. 
ane  are  also  produced  in  these  inflammation  models  (16, 
18,  19,  25),  our  passive  immunization  data  suggest  that 
PGE  2 appears necessary for the full and sustained expression 
of edema and hyperalgesia in  affected tissue.  This conclu- 
sion is substantiated by reconstitution experiments in which 
exogenous PGE2,  but not  PGI2, fully restored edema for- 
mation  in  carrageenan-challenged  rats  that  were  depleted 
of endogenous PGs with indomethacin. Ferreira et al. (9-11) 
similarly showed  that  while  infusion  of purified  PGE  2 or 
PGI  2 elicited hyperalgesia in rodents and man, the effects of 
PGE2 were sustained for several hours while those of PGI2 
were short lived. Our results suggest that analogous studies 
will  help  define  the  contribution  of endogenous  PGI  2 to 
edema  and  hyperalgesia.  In  this  regard,  Smith  et  al.  (29) 
have  previously  demonstrated  the  effectiveness  of poly- 
clonal antibodies in neutralizing the hypotensive activity of 
PGI  2 in vivo. 
In addition to addressing the role of PGE2 in promoting 
inflammatory symptoms, we examined the effect of 2B5 on 
inflammatory cytokine production in rat adjuvant arthritis. 
Our previous study showed that  the  marked upregulation 
of IL-6 RNA  production  in  this  model was inhibited  by 
COX-2 inhibitors  (25).  Passive immunization experiments 
with  2B5  extend  these  findings  by implicating PGE2  as  a 
critical  regulator  of IL-6 production  in  adjuvant  arthritis. 
We  observed  that  the  therapeutic  treatment  of rats  with 
2B5, but not MOPC control protein, significantly reduced 
IL-6  R.NA  expression  in  arthritic  paws  and  IL-6 protein 
levels in serum. These findings are consistent with the abil- 
ity of PGE2 and other cAMP-inducing agents to upregulate 
cellular levels ofIL-6 RNA in vitro (30,  31). 
In contrast to its positive effect on IL-6 synthesis, PGE  2 
may  downregulate  TNF  P,  NA  and  protein  synthesis  by 
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monocytes and lymphocytes in vitro (32,  33).  A  similar m 
vivo role for PGE  2 has been suggested by the enbarming ef- 
fect  of NSAIDs  on  TNF  production  in  LPS-challenged 
mice (34,  35).  However, we failed to reproducibly observe 
enhanced levels of TNF R.NA in the paws of indometha- 
cin- or 2B5-treated rats 21 d after adjuvant injection. Simi- 
lar findings were obtained in the analysis  of TNF R.NA in 
animals with late-stage adjuvant arthritis  that  were treated 
with COX-2 inhibitors  (25).  This apparent discrepancy in 
the  role of PGE2 in regulating TNF  in  various inflamma- 
tion models may relate to differences in inflammatory stim- 
uli, as well the acute vs. chronic nature of the inflammatory 
responses. It is plausible that PGE2 may downregulate TNF 
production in the early stages of the inflammatory respond, 
whereas its effect may become less important as other me- 
diators are released later in the disease process. 
Considerable  evidence  indicates  that  the  inflammatory 
effects of PGE  2 are  mediated  through  G  protein-coupled 
EP receptors on cell plasma membranes (27,  36). Recently, 
an additional mechanism has been proposed in which PGs 
may exert their biologic effects directly within the nucleus 
(36).  Studies  by Smith  et  al.  have identified  the  COX-2 
enzyme in functionally active form in association with the 
nuclear  membrane  (37-39).  In  addition,  other  enzymes 
such  as  cytosolic  phospholipase  A2  have  been  shown  to 
translocate  to  the  nuclear  membrane  where  arachidonic 
acid is released as a substrate for COX-2-mediated PG syn- 
thesis  (40).  These  intriguing  observations  have  raised  the 
possibility  that  newly  synthesized  PGs  may  act  directly 
within the nucleus in addition to activating G protein--cou- 
pled receptors on the cell surface. While NSAIDs would be 
ineffective  in  distinguishing  the  relative  contribution  of 
these signaling pathways, it is likely that neutralizing mAbs would  bind  to  and  neutralize  the  activity of extracellular 
PG  without  affecting  PG  acting  within  the  cell.  Conse- 
quently,  the antiinflammatory properties of 2B5  described 
herein suggest that potentiation of edema, hyperalgesia, and 
IL-6  production  requires  an  interaction  of  extracellular 
PGE 2  with  cell-surface  receptors.  Whether  signals  trans- 
duced by PGE2  through EP receptors are sufficient to po- 
tentiate edema and hyperalgesia, or whether additional sig- 
nals  are  transduced  through  nuclear  PGs,  remains  an 
interesting subject for future experimentation. 
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